Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Anti-Neutrophil Extracellular Trap Antibodies and Impaired Neutrophil Extracellular Trap Degradation in Antiphospholipid Syndrome.

Arthritis & rheumatology (Hoboken, N.J.)·2020
Same author

Increased Adhesive Potential of Antiphospholipid Syndrome Neutrophils Mediated by β2 Integrin Mac-1.

Arthritis & rheumatology (Hoboken, N.J.)·2019
Same author

Adenosine receptor agonism protects against NETosis and thrombosis in antiphospholipid syndrome.

Nature communications·2019
Same author

Cryptic conspirators: a conversation about thrombocytopenia and antiphospholipid syndrome.

Current opinion in rheumatology·2019
Same author

NCCN Guidelines Insights: Cancer-Associated Venous Thromboembolic Disease, Version 2.2018.

Journal of the National Comprehensive Cancer Network : JNCCN·2018
Same author

Activated signature of antiphospholipid syndrome neutrophils reveals potential therapeutic target.

JCI insight·2017

Related Experiment Video

Updated: Jul 18, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

Management of hereditary hypercoagulable disorders.

Paula L Bockenstedt1

  • 1University of Michigan, 200 Barton N Drive, Ann Arbor, MI 48105, USA. pbockens@umich.edu

Hematology. American Society of Hematology. Education Program
|November 25, 2006
PubMed
Summary

Managing hereditary hypercoagulable disorders now involves individualized risk-benefit analysis for thrombosis. Thrombophilia screening in specific populations may improve outcomes for venous thromboembolism patients.

Related Experiment Videos

Last Updated: Jul 18, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

Area of Science:

  • Hematology
  • Genetics
  • Clinical Medicine

Background:

  • Hereditary hypercoagulable disorders present complex thrombosis risks.
  • Clinical management has shifted from universal anticoagulation to personalized strategies.
  • Understanding gene-environment interactions is key to thrombosis prediction.

Purpose of the Study:

  • To review the evolving clinical management of hereditary hypercoagulable disorders.
  • To highlight the role of thrombophilia in various clinical scenarios.
  • To emphasize risk-benefit assessment in anticoagulation decisions.

Main Methods:

  • Literature review of studies on hereditary hypercoagulable disorders and thrombosis.
  • Analysis of risk factors for venous thromboembolism.
  • Evaluation of thrombophilia screening in clinical practice.

Main Results:

  • Lifelong anticoagulation is no longer the sole recommendation for venous thromboembolism.
  • Thrombophilic disorders significantly increase risks in pregnancy, transplantation, and with medical devices.
  • Individualized risk assessment is crucial for managing thrombosis risk versus anticoagulation risks.

Conclusions:

  • Clinical management requires a nuanced approach, balancing thrombosis risk with bleeding risk from anticoagulation.
  • Thrombophilia testing in select patient groups may guide treatment decisions and improve outcomes.
  • Further research into complex factor interactions will refine personalized thrombosis management.